Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 0.78 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | SGK1 | O00141 | 1/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
| ▸ | PRKCG | P05129 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | AKT2 | P31751 | 1/20 | 0.55 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.55 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813736 | 0.94 | CHEK1 (0.78) | CHEK1 | |
| SCHEMBL6794435 | 0.91 | CHEK1 (0.74) | CHEK1KDRSGK1CHEK2PRKCG | |
| SCHEMBL4815710 | 0.87 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL4814833 | 0.87 | CHEK1 (0.70) | CHEK1KDR | |
| SCHEMBL4807037 | 0.87 | CHEK1 (0.84) | CHEK1 | |
| SCHEMBL6194516 | 0.86 | CHEK1 (1.00) | CHEK1KDRSGK1CHEK2PRKCG | |
| SCHEMBL6789945 | 0.85 | CHEK1 (0.80) | CHEK1KDRSGK1CHEK2PRKCG | |
| SCHEMBL6787230 | 0.82 | CHEK1 (1.00) | CHEK1KDRSGK1CHEK2PRKCG | |
| SCHEMBL4815837 | 0.82 | CHEK1 (1.00) | CHEK1KDR | |
| SCHEMBL4810532 | 0.81 | CHEK1 (0.75) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CHEK1 73/4885KDR 1024/4885SGK1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.